Engineered cell strain and application thereof
By constructing engineered cell lines overexpressing CD8 and TCR and co-culture with antigen-expressing cell lines, combined with luciferase detection, the problems of long and high biological activity cycles and high cost of detecting vaccines in the prior art are solved, and rapid Efficient detection of vaccine biological activity.
Patent Information
- Application Number
- CN202411233558.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art has problems with long detection cycles, low throughput and high cost in detecting the biological activity of vaccines, especially in in vivo detection, where it is impossible to effectively detect the efficiency of antigen presentation by MHC and the cellular localization of antigens.
An engineered cell line was developed to construct a cell line that overexpresses CD8 and TCR, combined with viral transfection, and used to co-culture with antigen-expressing cell lines, using luciferase as a detection reagent to detect the biology of vaccines. active.
The detection of vaccine biological activity with short detection time and high throughput is achieved, which is especially suitable for polypeptide and mRNA vaccines, and does not require a long development cycle and high cost.
Smart Images

Figure CN119020295A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to an engineered cell line and application thereof. Background Art
[0002] Currently, vaccine drugs come in many forms, including peptides, DNA, mRNA, and DC. Among them, mRNA-LNP is one of the vaccine drugs with extremely high clinical value and commercial prospects. At present, the detection of the biological activity of vaccine drugs is mainly carried out in experimental animals. Taking mRNA-LNP as an example, after immunization in humanized mice, the immune response effect can be detected by tetramer staining, ELISpot, and intracellular factor detection. However, the in vivo detection method has a long cycle, low throughput, and high cost. The corresponding in vitro detection methods can only indirectly detect the expression abundance of antigens through Elisa or flow cytometry. These methods are selective for the cellular localization of antigens, require ready-made commercial antibodies, and cannot detect the efficiency of antigen presentation by MHC, so they have great limitations.
[0003] Therefore, developing an engineered cell line that can be used to detect the biological activity of vaccines is of vital importance in this field. Summary of the invention
[0004] To make up for the deficiencies of the prior art, the present invention provides an engineered cell line and application thereof.
[0005] To achieve the above object, the present invention adopts the following technical solution:
[0006] The first aspect of the present invention provides an engineered cell strain, which is deposited in the General Microbiological Center of China National Microbiological Culture Collection Administration with a deposit number of CGMCC No.46022.
[0007] The second aspect of the present invention provides a progeny cell line derived from the engineered cell line described in the first aspect of the present invention.
[0008] The third aspect of the present invention provides a reagent, which comprises the engineered cell line described in the first aspect of the present invention or the progeny cell line described in the second aspect of the present invention.
[0009] The fourth aspect of the present invention provides a kit, which comprises the engineered cell line described in the first aspect of the present invention, the progeny cell line described in the second aspect of the present invention, or the reagent described in the third aspect of the present invention.
[0010] The fifth aspect of the present invention provides any of the following uses of the engineered cell line described in the first aspect of the present invention or the progeny cell line described in the second aspect of the present invention:
[0011] (1) Detect the biological activity of the vaccine;
[0012] (2) Preparation of products for testing the biological activity of vaccines;
[0013] (3) Screening of vaccine antigens;
[0014] (4) Preparation and screening of vaccine antigens;
[0015] (5) Screening of vaccine enhancing elements;
[0016] (6) preparing products for screening vaccine enhancing elements;
[0017] (7) Screening of vaccine cap structures;
[0018] (8) Prepare and screen products for vaccine cap structures;
[0019] (9) Screening for vaccine base modifications;
[0020] (10) Preparation and screening of vaccine base-modified products;
[0021] (11) Screening UTR regions;
[0022] (12) preparing products for screening UTR regions;
[0023] (13) Screening of PolyA structure;
[0024] (14) preparing and screening products of PolyA structure;
[0025] (15) Screening for codon-optimized sequences;
[0026] (16) preparing products for screening codon optimized sequences;
[0027] (17) Screening of circular mRNA structures;
[0028] (18) preparing products for screening circular mRNA structures;
[0029] (19) Screening for self-replicating mRNA;
[0030] (20) preparing and screening products for self-replicating mRNA;
[0031] (21) Screening delivery systems;
[0032] (22) preparing products for screening delivery systems;
[0033] (23) Screening of cationic liposomes;
[0034] (24) preparing and screening cationic liposome products;
[0035] (25) Screening TCR;
[0036] (26) preparing products for screening TCRs;
[0037] (27) Screening CAR molecular design;
[0038] (28) Prepare products for screening CAR molecular design.
[0039] The sixth aspect of the present invention provides a method for detecting the biological activity of a vaccine, the method comprising using the engineered cell line described in the first aspect of the present invention for detection.
[0040] Furthermore, the method comprises co-culturing the engineered cell line described in the first aspect of the present invention with a cell line expressing an antigen to detect the biological activity of the vaccine.
[0041] Furthermore, the cell lines expressing antigens include natural cell lines and engineered cell lines.
[0042] Furthermore, the antigen-expressing cell line is selected from natural or engineered tumor cell lines.
[0043] Furthermore, the natural or engineered tumor cell line is selected from the HepG2 cell line.
[0044] Furthermore, the method also includes using a detection reagent to detect the biological activity of the vaccine.
[0045] Furthermore, the detection reagent is selected from luciferase.
[0046] Furthermore, the effector-target ratio of the co-culture is (0.5-20):1.
[0047] Furthermore, the effector-target ratio of the co-culture is (3-10):1.
[0048] Furthermore, the effector-target ratio of the co-culture is 5:1.
[0049] Furthermore, the co-cultivation time is 2-48 hours.
[0050] Furthermore, the co-cultivation time is 6 hours.
[0051] Furthermore, the culture medium used in the co-cultivation is a basal culture medium.
[0052] Furthermore, the basic culture medium is selected from 1640 culture medium.
[0053] Furthermore, the 1640 culture medium also includes FBS.
[0054] Furthermore, the vaccine is selected from T cell immune vaccine.
[0055] Furthermore, the types of vaccines include polypeptide vaccines, mRNA vaccines, DNA vaccines, and DC vaccines.
[0056] Furthermore, the vaccine is selected from polypeptide vaccines and mRNA vaccines.
[0057] Furthermore, the mRNA vaccine includes an mRNA-LNP vaccine.
[0058] Furthermore, the biological activity of the vaccine includes the efficiency of antigen presentation and the degree of T cell activation.
[0059] The seventh aspect of the present invention provides a method for constructing the engineered cell line described in the first aspect of the present invention, the method comprising constructing a cell line overexpressing CD8 and TCR.
[0060] Furthermore, a cell line overexpressing CD8 and TCR was constructed using viral transfection.
[0061] Biomaterial deposit information:
[0062] Classification: Homo sapiens
[0063] Depository: China General Microbiology Center (CGMCC)
[0064] Deposit address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing
[0065] Storage date: July 26, 2024
[0066] Deposit number: CGMCC No.46022
[0067] Advantages and beneficial effects of the present invention:
[0068] The engineered cell line constructed by the present invention can be used to detect the biological activity of vaccines, especially the biological activity of polypeptide vaccines and mRNA vaccines. The detection time is short, the detection throughput is high, and a long development cycle and development cost are not required. BRIEF DESCRIPTION OF THE DRAWINGS
[0069] Figure 1 is the pZXK-CD8 and pZXK-MAGE-A1_TCR-1367 plasmid map;
[0070] Figure 2 This is the positive group detection diagram of NFAT-Jurkat-CD8-MAGE-A1_TCR mixed clone strain;
[0071] Figure 3This is the NFAT-Jurkat-CD8-MAGE-A1_TCR monoclonal strain selection diagram;
[0072] Figure 4 This is a graph of in vitro activity assays of MAGE-A1 scanning peptides and mRNA;
[0073] Figure 5 This is a graph showing the in vitro activity detection of MAGE-A1-LNP. DETAILED DESCRIPTION
[0074] The definitions of some terms used in this specification are provided below. Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0075] The present invention provides a kit, which comprises the above-mentioned engineered cell line, the above-mentioned progeny cell line or the above-mentioned reagent.
[0076] In one embodiment, the kit may optionally include one or more components, such as instructions for use, devices, and additional reagents (e.g., sterile water or saline solution). In some embodiments, the kit may also contain reagents for sample collection, sample preparation and processing, and / or reagents for quantifying the amount of one or more surface markers in the sample, including but not limited to detection reagents, such as antibodies, buffers, enzyme staining substrates, or other materials (e.g., slides, containers, microtiter plates).
[0077] In one embodiment, the kit can be provided as an article comprising packaging materials for packaging cell lines or one or more other components. For example, the kit can contain containers, bottles, tubes, vials, and any packaging materials suitable for separating or organizing the components of the kit. One or more containers can be made of a variety of materials (such as glass or plastic). In some embodiments, one or more containers contain cell lines or other compositions.
[0078] In one embodiment, screening cationic liposomes refers to screening the biological activity of mRNA vaccines prepared with different cationic liposomes.
[0079] In one embodiment, screening for codon-optimized sequences refers to screening for the biological activity of different sequences after codon optimization of nucleic acid vaccines.
[0080] In one embodiment, screening vaccine cap structures refers to screening the biological activity of mRNA vaccines with different cap structures.
[0081] In one embodiment, screening for vaccine base modifications refers to screening the biological activity of mRNA vaccines with different base modifications.
[0082] In one embodiment, screening circular mRNA structures refers to the detection of biological activity of circular mRNA vaccines.
[0083] In one embodiment, screening for self-replicating mRNA refers to the detection of biological activity of self-replicating mRNA vaccines.
[0084] In one embodiment, the cap structure is a special structure located at the 5' end produced by eukaryotic organisms during post-transcriptional modification. The 5' end cap contains a 7-methylguanosine connected to the 5' end of the mRNA through a triphosphate bridge. The cap structure wraps around the 5' end of the mRNA to protect it from degradation by exonucleases; it can also promote the cyclization of the mRNA and recruit ribosomes to initiate the translation process.
[0085] In one embodiment, the untranslated region (UTR) includes two parts, 5'UTR and 3'UTR, which can regulate the translation and half-life of mRNA. The 5'UTR is between the cap structure and the coding region ORF, and its length and secondary structure will affect the efficiency of the translation initiation stage. The 3'UTR is located downstream of the coding region ORF, before the stop codon. The 3'UTR of eukaryotic mRNA is an important functional element, and plays an important role in translation regulation and mRNA localization.
[0086] In one embodiment, the coding region ORF starts with a start codon and ends with a stop codon. Every three bases constitute a codon, encoding one amino acid.
[0087] In one embodiment, the 3'UTR tail is a Poly A sequence. Similar to the cap structure, the Poly (A) tail can also protect the mRNA from being degraded by nuclease exonucleases. The tail structure is also involved in the translation and its regulation process, and can bind to polyadenylic acid binding protein (PABP) to form a ring complex, participating in the initiation process of translation.
[0088] In one embodiment, TCR (T cell receptor) is a receptor molecule on the surface of T cells, which specifically recognizes the antigen brain-MHC complex on antigen presenting cells and triggers T cell immune response.
[0089] In one embodiment, TCR screening includes TCR affinity screening, TCR specificity screening, TCR on / offtarget evaluation, TCR response strength screening, TCR stability screening, endogenous TCR knockout efficiency evaluation, and exogenous TCR expression evaluation.
[0090] In one embodiment, screening of CAR molecule design includes but is not limited to screening the antigen binding domain, hinge, transmembrane domain and intracellular signaling domain of CAR.
[0091] In one embodiment, the vaccine may be in the form of, but not limited to, polypeptide vaccines, mRNA vaccines, DNA vaccines, and DC vaccines.
[0092] In a preferred embodiment, the vaccine is in the form of a polypeptide vaccine or an mRNA vaccine.
[0093] The present invention provides a method for detecting the biological activity of a vaccine, the method comprising co-culturing the engineered cell strain with a cell line expressing an antigen to detect the biological activity of the vaccine.
[0094] In one embodiment, the cell line expressing the antigen includes any type of natural cell line or engineered cell line from any source.
[0095] In a preferred embodiment, the cell line expressing the antigen is selected from a natural or engineered tumor cell line.
[0096] In one embodiment, natural or engineered tumor cell lines include but are not limited to HepG2 cell line, Raji cell line, WIL2-S cell line, SU-DHL-10 cell line, BJAB cell line, SU-DHL-4 cell line, P30 / OHK cell line, P116 cell line, MUTZ-3 cell line, SUPB15 cell line, SNK6 cell line, SK-MEL-28 cell line, C8161 cell line, RPMI-7951 cell line, HeLa cell line, A549 cell line, MCF7 cell line, PC12 cell line, HT1080 cell line, H460 cell line, H146 cell line, T-47D cell line, ZR-75-1 cell line, MKN-45 cell line, SGC-7901 cell line, CT26 cell line, HCT-8 cell line, L-428 cell line, L1326 cell line, Caov-3 cell line, and PA-1 cell line.
[0097] In a specific embodiment, the natural or engineered tumor cell line is selected from HepG2 cells.
[0098] In one embodiment, the co-culture refers to co-culturing two or more cells in the same environment so that the cells can communicate information with each other and support each other's growth and proliferation. The co-culture system of cells includes a direct co-culture system and an indirect co-culture system. The engineered cell line in this application is co-cultured with the cell line expressing the antigen in a direct co-culture system, and the two cells can be in direct contact with each other.
[0099] In one embodiment, the co-culture method comprises first inoculating the cell line expressing the antigen into the cell culture equipment, and then adding the engineered cell line to the cell culture equipment; or first adding the engineered cell line to the culture equipment, and then adding the cell line expressing the antigen to the cell culture equipment; or adding the engineered cells and the cell line expressing the antigen to the culture equipment at the same time.
[0100] In a preferred embodiment, the co-culture method is to first inoculate the cell line expressing the antigen into a cell culture device, and then add the engineered cell line into the cell culture device.
[0101] In one embodiment, a culture device or culture container refers to a container for containing a culture medium for culturing cells or tissues. The culture device can be glass or plastic. The culture device includes, but is not limited to, a culture dish, a culture bottle, or a culture plate; in some embodiments, the culture plate includes a single-slot and multi-slot culture plate; in some embodiments, the culture dish includes a chamber and a multi-chamber culture slide, a cover glass; in some embodiments, the culture bottle includes a flask, a test tube bottle, a roller bottle, and a spinner bottle.
[0102] The method also includes detecting the biological activity of the vaccine using a detection reagent.
[0103] In a preferred embodiment, the detection reagent is selected from luciferase.
[0104] In one embodiment, luciferase comes from organisms that can emit light in nature. It is a general term for a class of enzymes that can catalyze the oxidation of luciferin or fatty aldehydes to produce light. Depending on the source species, luciferase can be divided into firefly luciferase (FL) and bacterial luciferase (BL). The FL gene comes from fireflies and is expressed in Mg. 2+ , ATP, O 2 With the participation of, it catalyzes the oxidative decarboxylation of D-luciferin to produce activated oxyluciferin, which emits photons and produces fluorescence of 550-580nm.
[0105] In one embodiment, the effector-target ratio of the co-culture is (0.5-20):1.
[0106] In a preferred embodiment, the effector-target ratio of the co-culture is (3-10):1.
[0107] In one embodiment, the effector-target ratio refers to the ratio of the number of effector cells (engineered cell lines) to target cells (cell lines expressing antigens).
[0108] The culture medium used in the co-culture is any culture medium suitable for cell growth.
[0109] In a preferred embodiment, the culture medium suitable for cell growth is selected from a basal culture medium.
[0110] In one embodiment, the basal culture medium includes but is not limited to DMEM (Dulbecco's Modified Eagle Medium), DMEM / Nutrient Mixture F-12 (DMEM / F-12), Advanced DMEM / F-12, 1640 medium, IMDM (Iskoff's Modified Dulbecco's Medium), MEM (Minimum Essential Medium), BME (Basal Medium Eagle), KnockOut DMEM, KnockOut DMEM / F12, Advanced DMEM / F12, neurobasal.
[0111] In another embodiment, the basal medium includes a combination of the above exemplary basal media in various ratios.
[0112] In a specific embodiment, the basal culture medium is selected from 1640 medium.
[0113] In one embodiment, the biological activity of the vaccine includes antigen presentation efficiency and T cell activation degree.
[0114] The present invention provides a method for constructing the above-mentioned engineered cell line, which comprises constructing a cell line overexpressing CD8 and TCR.
[0115] In one embodiment, the method for constructing a cell line overexpressing TCR and CD8 includes but is not limited to plasmid transfection, viral transfection, liposome transfection, and transposon transfection.
[0116] In a preferred embodiment, the method for constructing a cell line overexpressing TCR and CD8 is selected from a plasmid transfection method and a viral transfection method.
[0117] In a more preferred embodiment, the method for constructing a cell line overexpressing TCR and CD8 is selected from viral transfection.
[0118] In one embodiment, viral transfection methods include but are not limited to lentiviral transfection methods, adenoviral transfection methods, and adeno-associated viral transfection methods.
[0119] In a specific embodiment, the viral transfection method is selected from lentiviral transfection method.
[0120] In one embodiment, the lentiviral transfection method comprises infection with plasmids expressing TCR and CD8.
[0121] In one embodiment, the vectors used in the viral transfection method include but are not limited to pIPMK, pXC1, pBHGE3, psPAX2, pMD2.G, pAAV-MCS, pAAV-RC, pHelper, pAAV-LacZ, pLK0.1-puro, pLK0.1-CMV-tGFP, pLKO.1-puro-CMV-tGFP, pLK0.1-CMV-Neo, pLK0.1-Neo, pLKO.1-Neo-CMV-tGFP, pLKO.1-puro-CM V-TagCFP, pLKO.1-puro-CMV-TagYFP, pLKO.l-puro-CMV-TagRFP, pLKO.1-puro-CMV-TagFP635, pLKO.-puro-UbC-TurboG FP, pLKO.l-puro-UbC-TagFP635, pLKO-puro-IPTG-1xLacO, pLKO-puro-IPTG-3xLacO, pLPl, pLP2, pLP / VSV-G, pENTR / U6.
[0122] In a specific embodiment, the vector used for the plasmid expressing TCR and CD8 is selected from pZXK.
[0123] The lentiviral transfection method further comprises the step of packaging the lentivirus before infection.
[0124] In one embodiment, the packaging cells used for lentiviral packaging are selected from 293 cells. The 293 cells include but are not limited to 293FT cells, 293LT cells, 293T cells, 293H cells, and 293FTM cells.
[0125] In a specific embodiment, the 293 cells are selected from 293FT cells.
[0126] The invention will be further described below in conjunction with specific examples. It should be understood that the specific embodiments described herein are presented by way of example and are not intended to limit the invention. The main features of the invention may be used in a variety of embodiments without departing from the scope of the invention.
[0127] Example
[0128] 1. Experimental Materials
[0129] 1) Cell lines and culture media: NFAT-Jurkat cell line was purchased from Nanjing Novezan Biotechnology Co., Ltd.; HepG2 cell line was purchased from Zhejiang Meisen; 293FT cell line was purchased from Beina Biotechnology; RPMI-1640 culture medium was purchased from Thermo Fisher Scientific with a catalog number of 11875-093; DMEM culture medium was purchased from ThermoFisher Scientific with a catalog number of C12430500BT; and fetal bovine serum was purchased from Cellsera with a catalog number of AU-FBS / FS.
[0130] 2) The raw materials required for plasmid construction include: pZXK plasmid purchased from Nanjing GenScript Biotechnology Co., Ltd.; restriction endonucleases NheI and BamHI purchased from New England Biolabs; PCR reagent KOD-Plus-Neo purchased from Toyobo (Shanghai) Biotechnology Co., Ltd., catalog number KOD-401; T4 DNA ligase purchased from New England Biolabs; UE DNA gel recovery kit purchased from Suzhou Uni-Easy Biotechnology Co., Ltd.; endotoxin-free plasmid extraction kit (enhanced) purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.
[0131] CD8α chain-P2A-CD8β chain (CD8) CDS sequence:
[0132] ATGGCGCTGCCCGTCACCGCGCTGCTGCTTCCCCTGGCGCTGCTCCTGCATGCCGCTCGGCCCTCTCAGTTCCGCGTGTCCCCTCTGGACCGCACCTGGAACCTGGGCGAGACCGTGGAGCTGAAGTGCCAGGTCCTCCTGTCGAACCCGACCAGCGGGTGCAGTTGGCTATTCCAGCCACGGGGCGCTGCAGCCAGCCCCACCTTCCTGCTCTACCTGTCTCAGAACAAGCCCAAGGCCGCCGAGGGCCTCGACACCCAGAGGTTTTCGGGCAAACGTCTGGGTGATACCTTCGTCTTAACCTTGTCCGATTTCAGACGCGAGAACGAGGGCTACTACTTCTGTTCCGCCCTGTCAAATTCTATCATGTATTTCAGTCACTTTGTTCCGGTGTTCCTGCCTGCCAAGCCTACCACTACTCCGGCGCCGAGGCCCCCAACCCCTGCTCCTACTATCGCATCCCAGCCGTTGAGCTTGAGGCCTGAGGCCTGCAGGCCTGCGGCGGGCGGCGCCGTCCACACCCGTGGTTTAGACTTCGCCTGCGACATCTACATTTGGGCGCCCCTGGCCGGCACTTGCGGGGTGCTTCTGCTGTCCTTGGTGATCACTCTTTACTGTAACCACCGCAACCGCCGGCGCGTCTGTAAGTGCCCACGCCCGGTTGTAAAGTCGGGTGACAAACCATCGCTGTCCGCTCGCTACGTGGGTTCTGGC GCAACAAACTTCTCCCTGCTCAAACAGGCCGGGGATGT GGAGGAGAATCCAGGGCCCATGCGTCCCCGCCTTTGGCTCCTCCTTGCTGCGCAGCTGACCGTCCTGCACGGCAACTCCGTGCTGCAGCAGACGCCGGCCTACATCAAGGTGCAGACCAACAAGATGGTGATGCTGTCATGCGAGGCTAAAATCTCTCTGAGCAACATGCGCATCTATTGGCTACGCCAGCGCCAGGCCCCCAGCTCCGACAGCCACCACGAGTTCCTGGCTCTTTGGGATTCCGCCAAAGGCACCATCCATGGAGAGGAGGTGGAACAGGAGAAGATAGCCGTGTTCCGCGACGCGTCCCGCTTCATTCTCAACCTGACCTCCGTCAAGCCGGAGGACTCTGGAATTTACTTTTGTATGATCGTGGGGTCCCCCGAACTGACCTTCGGCAAGGGCACCCAACTTTCGGTAGTGGACTTTCTGCCTACCACAGCCCAACCCACCAAGAAGTCCACTCTCAAGAAGCGCGTGTGCCGACTGCCCCGCCCTGAAACCCAGAAGGGCCCCCTGTGCTCCCCCATCACGCTGGGATTGCTGGTGGCAGGCGTACTGGTGCTGCTGGTTTCTCTCGGTGTGGCCATCCACCTGTGCTGCCGACGGCGTCGTGCTAGACTGCGCTTCATGAAGCAGTTTTACAAGTAA(SEQ ID NO:1)
[0133] MAGE-A1_TCR-1367 sequence:
[0134]
[0135] MAGE-A1_TCR-1405 sequence:
[0136]
[0137]
[0138] MAGE-A1 epitope CDS sequence:
[0139] ATGTACGAGTTTCTGTGGGGCCCCCGCGCCCTGGCAGAGACCTCTTACGTGAAGGTGCTGGAGTACGTGATCAAGGTCTCTGCCAGGGTGCGCTGA (SEQ ID NO: 5)
[0140] PCR primers
[0141] CD8-PCR-F1:
[0142] GTGTCCCCTGGATACCCGTATTCTAGAGCTAGCGCCACCATGGCGCTGCCCGTC(SEQ ID NO:6)
[0143] CD8-PCR-R1:
[0144] CCGGTCATGGTCAATTGGGCCGCGGATCCTTACTTGTAAAACTGCTTCATGAAGCGC(SEQ ID NO:7)
[0145] MAGE-A1_TCR-PCR-F1:
[0146] GTGTCCCCTGGATACCCGTATTCTAGAGCTAGCGCCACCATGGGAATCAGACTGCTG(SEQ ID NO:8)
[0147] MAGE-A1_TCR-PCR-R1:
[0148] CCGGTCATGGTCAATTGGGCCGCGGATCCTCAGCTGGACCACAGTCTCAGGGTCATC(SEQ ID NO:9)
[0149] 3) Materials for constructing lentiviral cell lines include: second-generation lentiviral packaging plasmids psPAX2 and pMD2.G were purchased from Nanjing GenScript Biotechnology Co., Ltd.; Puromycin was purchased from MedChemExpress with the catalog number HY-B1743A; LipofectamineTM 3000 transfection reagent was purchased from Thermo Fisher Scientific with the catalog number L3000015; Opti-MEM reduced serum medium was purchased from Thermo Fisher Scientific with the catalog number 31985062.
[0150] 4) Electroporation kit: Neon TM The 100 μL electroporation kit was purchased from Thermo Fisher Scientific with the catalog number MPK10096.
[0151] 5) NFAT-Jurkat stimulation reagents include: PMA + ionomycin (PMA and Ionomycin) purchased from Shenzhen Dakoway Biotechnology Co., Ltd., catalog number 2030421; the HLA-A*02:01 restricted epitope of MAGE-A1 is KVLEYVIKV (SEQ ID NO: 10), using a 30-mer scanning peptide with the sequence YEFLWGPRALAETSYVKVLEYVIKVSARVR (SEQ ID NO: 11), purchased from Nanjing GenScript Biotechnology Co., Ltd.
[0152] 6) Flow cytometry antibodies include: HLA-A*02:01MAGE-A1 Tetramer-KVLEYVIKV-APC purchased from MBL with the catalog number TB-M070-2; BV510 Mouse Anti-Human CD8 purchased from BD Biosciences with the catalog number 563919.
[0153] 7) Luciferase Assay Kit: Bio-Lite Luciferase Assay System was purchased from Nanjing Novezan Biotechnology Co., Ltd. with the product number DD1201-02.
[0154] 2. Experimental methods
[0155] Step 1: Construction of NFAT-Jurkat-CD8-MAGE-A1_TCR stable cell line
[0156] Plasmid construction: Primers were designed to use plasmids pIPMK-CD8 and pIPMK-MAGE-A1_TCR-1367 as templates, CD8 and MAGE-A1_TCR-1367 were amplified by PCR reaction, and the PCR products were subjected to nucleic acid gel electrophoresis to cut the corresponding bands of CD8 and MAGE-A1_TCR. The PCR product was recovered by a DNA gel recovery kit to obtain PCR products of CD8 and MAGE-A1_TCR with restriction sites on both sides. Then, the pZXK plasmid (vector) and the PCR product were digested with restriction endonucleases NheI and BamHI to expose the sticky ends. The digested vector fragments and PCR products were purified by gel retrieval. Then, the digested CD8 and MAGE-A1_TCR were connected to the vector with T4 ligase. The ligated products were transformed into competent cells. After plating and growing in a culture plate with resistance, single clones were selected for sequencing. After the monoclonal strain with correct sequencing was selected for expansion culture, the plasmid was extracted by an endotoxin-free plasmid extraction kit for mRNA preparation. The structure of the plasmid is shown in the figure below. Figure 1 shown.
[0157] Lentivirus packaging: 293FT cells were cultured in a T175 culture flask until the cell confluence reached 50-60%, and Lipo3000 and P3000 were prepared respectively. After preparation, they were allowed to stand at room temperature for 5 minutes. The two were mixed evenly and allowed to stand at room temperature for 30 minutes. Then, they were slowly added to the cell culture flask to be packaged with a pipette and placed in a CO2 chamber. 2 Culture in an incubator (Lipo3000 formula: add 25 μL of Lipo3000 to 500 μL Opti-MEM, P3000 formula: 500 μL Opti-MEM, 50 μL P3000, 6.25 μg of pZXK-CD8 or pZXK-MAGE-A1_TCR-1367 plasmid, 12.5 μg of psPAX and 6.25 μg of pMD2.G). Collect the supernatant 48h and 72h after plasmid transfection (add 20mL of fresh culture medium after collecting the supernatant 48h), centrifuge at 4500rpm and 4℃ for 5min to remove cell debris and other precipitates, then use a 0.22μM vacuum filter bottle to remove impurities from the supernatant, add 1 / 5 of the total volume of PEG8000 concentration reagent to the filtered solution, shake to mix, place in a 4℃ refrigerator for overnight concentration and sedimentation, then transfer to a 50mL centrifuge tube, centrifuge at 4500rpm and 4℃ for 50min, discard the supernatant, turn the centrifuge tube upside down on a paper towel for 2-3min, control the liquid as much as possible, add 200μL of pre-cooled D-PBS to resuspend, and then divide into 1.5mL centrifuge tubes, 50μL / tube, store at -80℃ or use directly to infect target cells.
[0158] Lentivirus infection: 3E5 NFAT-Jurkat cells were inoculated into 12-well plates, 1 mL of culture medium, 5 μL of polybrene infection reagent and 50 μL of purified lentivirus were added and mixed, and then incubated in CO 2 Culture in an incubator, replace the culture medium within 12-24 hours, and after expanded culture, flow cytometry is used to detect mixed clones with a higher proportion of CD8 and MAGE-A1_TCR positive cells for monoclonal screening.
[0159] Monoclonal screening: Expanded cultured NFAT-Jurkat cells were single-cell sorted into 96-well plates and cultured in CO 2 The cells were expanded and cultured in an incubator, and the monoclonal strains with the best expression of CD8 and MAGE-A1_TCR were selected by flow cytometry for expansion or preservation.
[0160] Tetramer staining: Resuspend about 3-10E5 test cells in 100 μL of PBS with 2 μL of Tetramer dye, stain for 15-30 minutes in the dark, wash with 1 mL of PBS and then detect on a microscope.
[0161] Step 2: In vitro activity assay of MAGE-A1 scanning peptides and mRNA
[0162] NFAT-Jurkat cell line culture: cultured with 1640 medium containing 10% FBS, maintaining the cell density in the range of 5E5-5E6, and cultured the cells for 2-3 generations before testing their functions.
[0163] HepG2 cell line culture: cultured in DMEM medium containing 10% FBS. When the cells grew to 90% density, the HepG2 cells were digested with 0.25% EDTA-trypsin and then passaged at a ratio of 1:5. After 2-3 generations of cell culture, the cells were used for electroporation or peptide loading.
[0164] Scanning peptide detection: HepG2 cells were incubated with 5 μg / mL MAGE-A1 scanning peptide overnight. On the second day, the HepG2 cells were digested and recounted, and 6E4 (E:T=5:1) peptide-loaded HepG2 cells were plated in each well of a 96-well flat-bottom cell culture plate. 3E5 NFAT-Jurkat-CD8-MAGE-A1_TCR cells were added. The culture medium was 200 μL 1640 culture medium containing 10% FBS. After co-culture for 6 hours, 100 μL luciferase detection reagent was added and the fluorescence value was detected in a microplate reader.
[0165] mRNA detection: The prepared mRNA needs to be tested with Neon TM 100μL electroporation kit electroporation, specific operation with 100μL Neon TM4E5 HepG2 cells resuspended in 100μL R solution in the electrotransfer kit were added with 5μg of mRNA encoding full-length MAGE-A1 and mixed. After adding 3-5mL E2 solution (electrotransfer kit) to the electrotransfer cup, it was placed in the cup slot of the electrotransfer instrument. The cell suspension mixed with mRNA was carefully aspirated with a 100μL electrotransfer gun tip to avoid bubbles. The electrotransfer gun was inserted into the E2 solution of the electrotransfer instrument and electrotransferred under the voltage conditions of 1350mV, 10ms, and 4plus. After the electroporated HepG2 cells were cultured overnight in 10% FBS 1640 medium, the HepG2 cells were digested and recounted, and 6E4 (E:T=5:1) peptide-loaded or electroporated mRNA HepG2 cells were plated in each well of a 96-well flat-bottom cell culture plate. After culturing with 100 μL 1640 culture medium for 24 h, 3E5 NFAT-Jurkat-CD8-MAGE-A1_TCR cells were added and co-cultured for 6 h. The culture medium was 200 μL 1640 culture medium containing 10% FBS. After co-culturing for 6 h, 100 μL luciferase detection reagent was added, and the fluorescence value was detected in a microplate reader.
[0166] Step 3: In vitro activity detection of MAGE-A1-LNP
[0167] NFAT-Jurkat cell line culture: cultured with 1640 medium containing 10% FBS, maintaining the cell density in the range of 5E5-5E6, and cultured the cells for 2-3 generations before testing their functions.
[0168] HepG2 cell line culture: cultured with DMEM medium containing 10% FBS. When the cells grew to 90% density, the HepG2 cells were digested with 0.25% EDTA-trypsin and then passaged at a ratio of 1:5. After 2-3 generations of cell culture, the cells were used for electroporation or peptide loading.
[0169] Preparation of mRNA-LNP: mRNA was diluted with citrate buffer and filtered through a 0.22 μm filter, lipid was solvented with anhydrous ethanol and filtered through a 0.22 μm filter, coated into mRNA-LNP using Ignite Instrument, and the prepared mRNA-LNP was diluted with Tris-HCL buffer and concentrated by ultrafiltration tube.
[0170] mRNA-LNP detection: 6E4 HepG2 cells were plated into a 96-well plate and resuspended in 50 μL 1640 complete medium. LNP was diluted to 1 ng / mL, 5 ng / mL, 25 ng / mL, and 125 ng / mL in 50 μL serum-free 1640 medium. The diluted LNP was added to the cells and incubated in CO 2The cells were cultured overnight in a cell culture incubator, and 100 μL of fresh culture medium was replaced the next day; 3E5 electroporated CD8 and MAGE-A1_TCR NFAT-Jurkat cells were added and co-cultured for 6 hours in 200 μL 1640 culture medium containing 10% FBS. After co-culture for 6 hours, 100 μL of luciferase detection reagent was added, and the fluorescence value was detected in an ELISA instrument.
[0171] 3. Experimental results
[0172] Figure 1 Displays the plasmid structure used for lentiviral overexpression of CD8 and MAGE-A1_TCR-1367, CD8α chain-P2A-β chain ( Figure 1 A) or MAGE-A1_TCR-1367( Figure 1 B) After the enhancer is cloned, it is integrated with the Puromycin resistance gene between the 3'LTR of the HIV virus and can be packaged into a lentivirus for the construction of a gene overexpression cell line.
[0173] Figure 2 The CD8 and MAGE-A1-Tetramer flow cytometry results of NFAT-Jurkat cells infected with lentivirus are shown. As shown in the figure, the double positive rate of CD8 and MAGE-A1_TCR is 76.57%.
[0174] Figure 3 Among the 18 monoclonal strains selected, the double positive rate of monoclonal cells No. 4, 5, 6, 10 and 12 can reach more than 99%. The above monoclonal strains are cryopreserved, and monoclonal cells No. 4, 5 and 12 are selected for functional verification.
[0175] Figure 4 After 6 hours of co-culture of the constructed NFAT-Jurkat-CD8-MAGE-A1_TCR monoclonal strains 4 (mono4), 5 (mono5) and 12 (mono12) with HepG2 cells loaded with MAGE-A1 scanning peptide or electroporated with MAGE-A1 full-length mRNA, the fluorescence values were all upregulated, indicating that the NFAT-Jurkat-CD8-MAGE-A1_TCR stably transfected cell line can be used to detect the biological activity of peptides and mRNA.
[0176] like Figure 5As shown, LNPs with concentrations of 1 ng / mL, 5 ng / mL, 25 ng / mL and 125 ng / mL were incubated in vitro to present MAGE-A1 on the surface of HepG2 cells. Activation could be detected after co-culture with NFAT-Jurkat-CD8-MAGE-A1_TCR cells, and the LUC fluorescence reading was upregulated with increasing LNP concentrations. The results indicate that the NFAT-Jurkat-CD8-MAGE-A1_TCR stably transfected cell line can be used for in vitro detection of the biological activity of LNPs.
[0177] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. An engineered cell line, It is characterized in that The engineered cell strain is deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with the deposit number being CGMCC No.46022.
2. A progeny cell line derived from the engineered cell line of claim 1.
3. A reagent, It is characterized in that The reagent comprises the engineered cell line according to claim 1 or the progeny cell line according to claim 2.
4. A kit, It is characterized in that The kit comprises the engineered cell line according to claim 1, the progeny cell line according to claim 2 or the reagent according to claim 3.
5. Any of the following uses of the engineered cell line according to claim 1 or the progeny cell line according to claim 2: (1) Detect the biological activity of the vaccine; (2) Preparation of products for testing the biological activity of vaccines; (3) Screening of vaccine antigens; (4) Preparation and screening of vaccine antigens; (5) Screening of vaccine enhancing elements; (6) preparing products for screening vaccine enhancing elements; (7) Screening of vaccine cap structures; (8) Prepare and screen products for vaccine cap structures; (9) Screening for vaccine base modifications; (10) Preparation and screening of vaccine base-modified products; (11) Screening UTR regions; (12) preparing products for screening UTR regions; (13) Screening of PolyA structure; (14) preparing and screening products of PolyA structure; (15) Screening for codon-optimized sequences; (16) preparing products for screening codon optimized sequences; (17) Screening of circular mRNA structures; (18) preparing products for screening circular mRNA structures; (19) Screening for self-replicating mRNA; (20) preparing and screening products for self-replicating mRNA; (21) Screening delivery systems; (22) preparing products for screening delivery systems; (23) Screening of cationic liposomes; (24) preparing and screening cationic liposome products; (25) Screening TCR; (26) preparing products for screening TCRs; (27) Screening CAR molecular design; (28) Prepare products for screening CAR molecular design.
6. A method for detecting the biological activity of a vaccine, It is characterized in that The method comprises using the engineered cell line described in claim 1 for detection.
7. The method according to claim 6, It is characterized in that The method comprises co-culturing the engineered cell line according to claim 1 with a cell line expressing an antigen, and detecting the biological activity of the vaccine.
8. The method according to claim 7, It is characterized in that The cell lines expressing antigens include natural cell lines and engineered cell lines; Preferably, the cell line expressing the antigen includes a natural cell line and an engineered cell line; Preferably, the antigen-expressing cell line is selected from a natural or engineered tumor cell line; Preferably, the natural or engineered tumor cell line is selected from the HepG2 cell line; Preferably, the method further comprises detecting the biological activity of the vaccine using a detection reagent; Preferably, the detection reagent is selected from luciferase; Preferably, the effector-target ratio of the co-culture is (0.5-20):1; Preferably, the effector-target ratio of the co-culture is (3-10):1; Preferably, the effector-target ratio of the co-culture is 5:1; Preferably, the co-cultivation time is 2-48 hours; Preferably, the co-cultivation time is 6 hours; Preferably, the vaccine is selected from T cell immune vaccines; Preferably, the types of vaccines include polypeptide vaccines, mRNA vaccines, DNA vaccines, and DC vaccines; Preferably, the vaccine is selected from polypeptide vaccines and mRNA vaccines; Preferably, the mRNA vaccine comprises an mRNA-LNP vaccine; Preferably, the biological activity of the vaccine includes antigen presentation efficiency and T cell activation degree.
9. A method for constructing the engineered cell line according to claim 1, It is characterized in that The method comprises constructing a cell line overexpressing CD8 and TCR.
10. The method according to claim 9, It is characterized in that Cell lines overexpressing CD8 and TCR were constructed using viral transfection; Preferably, a cell line overexpressing CD8 and TCR is constructed using viral transfection.
Citation Information
Patent Citations
Cloning, expression and application of recombination human fibroblast growth factor-16 and determination method for biological activity of recombination human fibroblast growth factor-16
CN107012150A
Porcine circovirus gene modified attenuated strain as well as construction method and application thereof
CN113355292A
Cloned cell strain for determining biological activity of teriparatide
CN113736741A
Lentiviral vector for constructing cell strain model for screening drug activity and application of lentiviral vector
CN114836473A
